Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities: Challenge or opportunity?
Fertility-sparing treatments for patients with metabolic risk factors may have poor efficacy. However, the integration of anti-estrogen therapy with the metabolic-targeting interventions, like metformin, appears to improve the outcomes of fertility-preserving strategies in this patient population.
Authors
- Yifan Zhai (ORCID: https://orcid.org/0000-0003-1672-2262)
- Jianliu Wang
- Danhua Shen (ORCID: https://orcid.org/0000-0002-0380-5117)
- Yifan Feng (ORCID: https://orcid.org/0000-0002-1695-9668)
- Yijiao He (ORCID: https://orcid.org/0000-0001-7112-3743)
- Linlin Bo
- Rong Zhou (ORCID: https://orcid.org/0000-0002-7740-5378)
- Jingyi Zhou (ORCID: https://orcid.org/0009-0003-3892-5869)
- Yuanyuan Liu (ORCID: https://orcid.org/0000-0001-6862-1928)
- Yiqin Wang (ORCID: https://orcid.org/0000-0003-4714-774X)
- Li Tian (ORCID: https://orcid.org/0000-0003-0222-7076)
- Fan Yuan
- Xiaobo Zhang
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1097/cm9.0000000000003721
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17